Daiichi Sankyo Expands Research Agreement With MorphoSys
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo will expand its joint research agreement with Munich-based MorphoSys for its closely watched Human Combinatorial Antibody Library technology
You may also be interested in...
MorphoSys Gains Third Japanese Partner Through Astellas Deal
Astellas has licensed a monoclonal antibody library called HuCAL GOLD from MorphoSys, a Frankfurt, Germany-based mAb company, for use in its internal drug discovery programs. MorphoSys announced the deal, which could extend up to five years, March 28
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).